TY - JOUR
T1 - Muscle magnetic resonance imaging in myotonic dystrophy type 1 (DM1)
T2 - Refining muscle involvement and implications for clinical trials
AU - Garibaldi, Matteo
AU - Nicoletti, Tommaso
AU - Bucci, Elisabetta
AU - Fionda, Laura
AU - Leonardi, Luca
AU - Morino, Stefania
AU - Tufano, Laura
AU - Alfieri, Girolamo
AU - Lauletta, Antonio
AU - Merlonghi, Gioia
AU - Perna, Alessia
AU - Rossi, Salvatore
AU - Ricci, Enzo
AU - Alonso Perez, Jorge
AU - Tartaglione, Tommaso
AU - Petrucci, Antonio
AU - Pennisi, Elena Maria
AU - Salvetti, Marco
AU - Cutter, Gary
AU - Díaz-Manera, Jordi
AU - Silvestri, Gabriella
AU - Antonini, Giovanni
N1 - Funding Information:
The authors acknowledge support from the Associazione Italiana Miologia (AIM) and Associazione Italiana Sistema Nervoso Periferico (ASNP). S.R. received a fellowship partially granted by the A.I. Vi.P.S. Onlus (Associazione Italiana Vivere la Paraparesi Spastica). Open Access Funding provided by Universita degli Studi di Roma La Sapienza within the CRUI‐CARE Agreement.
Publisher Copyright:
© 2021 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
PY - 2021
Y1 - 2021
N2 - Background: Only a few studies have reported muscle imaging data on small cohorts of patients with myotonic dystrophy type 1 (DM1). We aimed to investigate the muscle involvement in a large cohort of patients in order to refine the pattern of muscle involvement, to better understand the pathophysiological mechanisms of muscle weakness, and to identify potential imaging biomarkers for disease activity and severity. Methods: One hundred and thirty-four DM1 patients underwent a cross-sectional muscle magnetic resonance imaging (MRI) study. Short tau inversion recovery (STIR) and T1 sequences in the lower and upper body were analyzed. Fat replacement, muscle atrophy and STIR positivity were evaluated using three different scales. Correlations between MRI scores, clinical features and genetic background were investigated. Results: The most frequent pattern of muscle involvement in T1 consisted of fat replacement of the tongue, sternocleidomastoideus, paraspinalis, gluteus minimus, distal quadriceps and gastrocnemius medialis. Degree of fat replacement at MRI correlated with clinical severity and disease duration, but not with CTG expansion. Fat replacement was also detected in milder/asymptomatic patients. More than 80% of patients had STIR-positive signals in muscles. Most DM1 patients also showed a variable degree of muscle atrophy regardless of MRI signs of fat replacement. A subset of patients (20%) showed a ‘marbled’ muscle appearance. Conclusions: Muscle MRI is a sensitive biomarker of disease severity alsofor the milder spectrum of disease. STIR hyperintensity seems to precede fat replacement in T1. Beyond fat replacement, STIR positivity, muscle atrophy and a ‘marbled’ appearance suggest further mechanisms of muscle wasting and weakness in DM1, representing additional outcome measures and therapeutic targets for forthcoming clinical trials.
AB - Background: Only a few studies have reported muscle imaging data on small cohorts of patients with myotonic dystrophy type 1 (DM1). We aimed to investigate the muscle involvement in a large cohort of patients in order to refine the pattern of muscle involvement, to better understand the pathophysiological mechanisms of muscle weakness, and to identify potential imaging biomarkers for disease activity and severity. Methods: One hundred and thirty-four DM1 patients underwent a cross-sectional muscle magnetic resonance imaging (MRI) study. Short tau inversion recovery (STIR) and T1 sequences in the lower and upper body were analyzed. Fat replacement, muscle atrophy and STIR positivity were evaluated using three different scales. Correlations between MRI scores, clinical features and genetic background were investigated. Results: The most frequent pattern of muscle involvement in T1 consisted of fat replacement of the tongue, sternocleidomastoideus, paraspinalis, gluteus minimus, distal quadriceps and gastrocnemius medialis. Degree of fat replacement at MRI correlated with clinical severity and disease duration, but not with CTG expansion. Fat replacement was also detected in milder/asymptomatic patients. More than 80% of patients had STIR-positive signals in muscles. Most DM1 patients also showed a variable degree of muscle atrophy regardless of MRI signs of fat replacement. A subset of patients (20%) showed a ‘marbled’ muscle appearance. Conclusions: Muscle MRI is a sensitive biomarker of disease severity alsofor the milder spectrum of disease. STIR hyperintensity seems to precede fat replacement in T1. Beyond fat replacement, STIR positivity, muscle atrophy and a ‘marbled’ appearance suggest further mechanisms of muscle wasting and weakness in DM1, representing additional outcome measures and therapeutic targets for forthcoming clinical trials.
KW - clinical trials
KW - CTG
KW - muscle atrophy and inflammation
KW - muscle MRI
KW - myotonic dystrophy type 1
UR - http://www.scopus.com/inward/record.url?scp=85120489892&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85120489892&partnerID=8YFLogxK
U2 - 10.1111/ene.15174
DO - 10.1111/ene.15174
M3 - Article
AN - SCOPUS:85120489892
JO - European Journal of Neurology
JF - European Journal of Neurology
SN - 1351-5101
ER -